Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer. NPJ Breast Cancer 2023 Aug 19;9(1):70

Date

08/20/2023

Pubmed ID

37598278

Pubmed Central ID

PMC10439887

DOI

10.1038/s41523-023-00576-5

Scopus ID

2-s2.0-85168485997 (requires institutional sign-in at Scopus site)   2 Citations

Abstract

Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients with metastatic breast cancer, but their effect on short and long-term kidney function is unknown. We found that early, mild estimated glomerular filtration rate (eGFR) decline was common in patients treated with CDK 4/6 inhibitors; however, severe kidney injury is rare and long-term eGFR decline is uncommon.

Author List

Hanna PE, Strohbehn IA, Moreno D, Harden D, Seethapathy R, Sawtell R, Wang Q, Ouyang T, Katz-Agranov N, Dinulos J, Wander SA, Gupta S, Sise ME

Author

Paul E. Hanna MD Assistant Professor in the Medicine department at Medical College of Wisconsin